Tissue Damage Clinical Trial
Official title:
Effect of High Doses of Vitamin C on the Tissular Reparation (Healing) in Patients Under Surgery in the "Hospital de Los Valles".
Verified date | September 2021 |
Source | Universidad San Francisco de Quito |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, randomize, double-blind, and placebo-controlled study to evaluate in patients with clinical criteria for any of the following open surgical procedure: (1) cesarean section; (2) aesthetic surgery like abdominoplasty; (3) orthopedic surgery; and (4) abdominal open surgery [excluding laparoscopic procedures] will be invited to receive either a high dose of vitamin C (12.5 g) three times (48 h pre-surgery, immediately before surgery and 48 h post-surgery) or its placebo, to evaluate the tissue repair process using an international validated instrument named Patient and Observer Scar Assessment Scale.
Status | Completed |
Enrollment | 80 |
Est. completion date | March 3, 2021 |
Est. primary completion date | March 3, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Older than 18 years. - Susceptible for any of the following surgical procedures: (1) cesarean section; (2) aesthetic abdominal plastic surgery; (3) orthopedic prosthetic replacement surgery - Voluntary consent to participate Exclusion Criteria: - Known allergy to the vitamin C - Known problems with wounds healing - Kidney disease (including lithiasis) or gout |
Country | Name | City | State |
---|---|---|---|
Ecuador | Hospital de los Valles | Quito | Pichincha |
Lead Sponsor | Collaborator |
---|---|
Universidad San Francisco de Quito | Biomolec Pharma |
Ecuador,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of linear scars | Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area) | initial assessment, two weeks after surgery | |
Primary | Evaluation of linear scars | Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area) | second assessment, one month after surgery | |
Primary | Evaluation of linear scars | Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area) | third assessment, three months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03040921 -
Uterine Transposition: Feasibility Study
|
N/A | |
Completed |
NCT04389047 -
Comparison of Two Mechanical Ventilation Modes on Oxygenisation
|
||
Enrolling by invitation |
NCT03123458 -
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders
|
Phase 1 |